Bone metastases in prostate cancer are often the cause of significant morbidity in patients with castrate-resistant disease, and several studies have shown significant pain palliation with systemic radionuclide treatment. The purpose of this review is to discuss the place of radionuclides in the dynamic treatment landscape of metastatic prostate cancer in light of new evidence demonstrating benefit beyond palliation.
Vengalil, S., O'Sullivan, J. M., & Parker, C. C. (2012). Use of radionuclides in metastatic prostate cancer: pain relief and beyond. Current opinion in supportive and palliative care, 6(3), 310-5. https://doi.org/10.1097/SPC.0b013e328355e082